Audience -All Patients & Families-Adults & Aging-Chapters-Donors & Supporters-Healthcare Providers-Kids & Young Adults-Men-Payers-Spanish Speaking Individuals-Undiagnosed-Women & Girls Type of Bleeding Disorder -All Bleeding Disorders-Hemophilia-Inhibitors-Rare Bleeding Disorders-Von Willebrand Disease Topic -Advocacy-Awareness-Blood & Product Safety-Bone & Joint Health-Community-COVID-19-Digital Health-Diversity, Equity & Inclusion-Fitness & Nutrition-Future Therapies-Health Equity-Healthcare Insurance-HIV & Hepatitis C-Mental Health-Pain Management-Sexual & Reproductive Health-Research-Treatment & Care 25 Oct Updated FDA Blood and Plasma Donation Guidelines: What the Bleeding Disorders Community Needs to Know Oct 25, 2023 - Oct 25, 2023 11 Oct "I'm Fine": A Panel Discussion Led by Patrick James Lynch Oct 11, 2023 - Oct 11, 2023 27 Sep Federal Update on Telehealth Policy Sep 27, 2023 - Sep 27, 2023 20 Sep Burden on parents of children with moderate or severe von Willebrand disease: The impact of clinical data Sep 20, 2023 - Sep 20, 2023 13 Sep From NHF to NBDF: A Time for Change Sep 13, 2023 - Sep 13, 2023 06 Sep HEMGENIX (etranacogene dezapavovec-drlb) Patient Eligibility and Treatment Steps Sep 6, 2023 - Sep 6, 2023 09 Aug BDC 2023 Sneak Peek Aug 9, 2023 - Aug 9, 2023 02 Aug Factor up: Discover the Possibility of Higher Factor VIII Levels for Longer Aug 2, 2023 - Aug 2, 2023 26 Jul The New WFH Shared Decision-Making Tool Jul 26, 2023 - Jul 26, 2023 19 Jul Gene Editing Jul 19, 2023 - Jul 19, 2023 12 Jul Corporate Giving 101 Jul 12, 2023 - Jul 12, 2023 14 Jun Hemophilia Gene Therapy: First, Do No Harm Jun 14, 2023 - Jun 14, 2023 07 Jun Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications? Jun 7, 2023 - Jun 7, 2023 31 May Learn More About HEMABiologic’s Latest Treatment Option for the Hemophilia Community May 31, 2023 - May 31, 2023 24 May The Evidence for Shared-Decision Making for Hemophilia Gene Therapy May 24, 2023 - May 24, 2023 17 May Gene Therapy: A Breakthrough Era for Hemophilia B. Introducing Hemgenix®️ (Etranacogene Dezaparvovec-Drlb) May 17, 2023 - May 17, 2023 10 May Recombinant Factor VIII FC Fusion Protein for First-time Immune Tolerance May 10, 2023 03 May Lentiviral Gene Therapy for Artemis-Deficient SCID May 3, 2023 - May 3, 2023 26 Apr Increasing Health Equity IQ Apr 26, 2023 - Apr 26, 2023 19 Apr 10 Things You Need to Know About Cannabis Apr 19, 2023 - Apr 19, 2023 12 Apr Raising the Bar for Joint Health Apr 12, 2023 - Apr 12, 2023 05 Apr Empowering the Community Through Knowledge and Resources Apr 5, 2023 - Apr 5, 2023 29 Mar National Research Blueprint: A Continued Conversation Mar 29, 2023 - Mar 29, 2023 22 Mar National Research Blueprint: An Introduction Mar 22, 2023 - Mar 22, 2023 Pagination First page Previous page Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Last page
25 Oct Updated FDA Blood and Plasma Donation Guidelines: What the Bleeding Disorders Community Needs to Know Oct 25, 2023 - Oct 25, 2023
20 Sep Burden on parents of children with moderate or severe von Willebrand disease: The impact of clinical data Sep 20, 2023 - Sep 20, 2023
06 Sep HEMGENIX (etranacogene dezapavovec-drlb) Patient Eligibility and Treatment Steps Sep 6, 2023 - Sep 6, 2023
02 Aug Factor up: Discover the Possibility of Higher Factor VIII Levels for Longer Aug 2, 2023 - Aug 2, 2023
07 Jun Managing Pregnant Women with Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications? Jun 7, 2023 - Jun 7, 2023
31 May Learn More About HEMABiologic’s Latest Treatment Option for the Hemophilia Community May 31, 2023 - May 31, 2023
24 May The Evidence for Shared-Decision Making for Hemophilia Gene Therapy May 24, 2023 - May 24, 2023
17 May Gene Therapy: A Breakthrough Era for Hemophilia B. Introducing Hemgenix®️ (Etranacogene Dezaparvovec-Drlb) May 17, 2023 - May 17, 2023
